Amicus Therapeutics Inc.
Amicus Therapeutics Reports Q2 2025 Financial Results and Corporate Updates
Summary
Amicus Therapeutics, Inc. reported strong financial results for the second quarter of 2025, with total revenue of $154.7 million, reflecting a growth of 18% at constant exchange rates (CER). Galafold revenue was $128.9 million, up 12% at CER, while Pombiliti + Opfolda revenue was $25.8 million, up 58% at CER. The company reiterated its financial guidance for 2025, including GAAP profitability in the second half of the year. Amicus also provided updates on regulatory approvals, licensing agreements, and clinical trial progress.
Profitelligence Alerts
Get alerts for FOLD
Be first to know when Amicus Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Amicus Therapeutics Inc.
Amicus Therapeutics Inc. is a biopharmaceutical company dedicated to developing advanced therapies for rare and orphan diseases. Its primary focus is on genetic disorders, particularly lysosomal storage disorders and other diseases resulting from improper protein folding within cells. Amicus leverages its proprietary technology platforms to create drug candidates that address unmet medical needs, providing innovative solutions for complex conditions like Fabry disease and Pompe disease. The company's commitment to patient-centric innovation aims to enhance the quality of life for individuals facing challenging health diagnoses. Situated within the biotechnology sector, Amicus plays a significant role in advancing novel treatment options, thereby impacting healthcare markets and potentially transforming the standard of care for rare genetic diseases. Founded in 2002, the company harnesses cutting-edge research and collaborations to foster groundbreaking developments in the therapeutic landscape uniquely shaped by the complexities of rare diseases.
Official SEC Documents
Advertisement